Cure My Disease

Don't miss your cure!

 Log in / Sign up

Why COVID-19 hits blood cancer patients harder: scientists map the immune clues

NCT ID NCT05683353

Knowledge-focused Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers at Peking University First Hospital are studying how the immune system responds to SARS-CoV-2 infection in people who have blood cancers compared with people who have no underlying diseases. The observational study enrolls 60 participants and collects clinical details, treatment information, and peripheral blood samples. By comparing immune function and infection mechanisms between the two groups, the team aims to identify potential drug targets that could help protect this vulnerable population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers map how blood cancers weaken the immune response to SARS-CoV-2, that knowledge could point toward drug targets or better ways to protect this vulnerable group.
What could go wrong
This is a small observational study of 60 people, so it can only describe patterns, not prove cause or test a treatment. Findings in this specific group may not apply to other patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hospitalized patients with SARS-CoV-2 positive hematologic tumors over 18 years old. People with SARS-CoV-2 positive without underlying diseases over 18 years old.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Clinical diagnosis of hematologic tumors Clinical diagnosis of SARS-CoV-2 infection Exclusion Criteria: \- Severe diseases associated with other systems

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic malignancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignancy SARS-CoV-2 infection

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.